Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Down 0.8% – Should You Sell?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) traded down 0.8% during mid-day trading on Friday. The company traded as low as $12.11 and last traded at $12.30. Approximately 553,484 shares were traded during trading, a decline of 7% from the average session volume of 597,667 shares. The stock had previously closed at $12.40.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BAYRY shares. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The stock’s fifty day moving average price is $13.53 and its 200-day moving average price is $12.63. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The firm has a market cap of $48.34 billion, a PE ratio of -24.12, a P/E/G ratio of 1.88 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts forecast that Bayer Aktiengesellschaft will post 1.27 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.